Decrease of Urotensin II activity can impact on the volume status in predialysis chronic kidney disease

References

• Charles CJ, Rademaker MT, Richards AM, et al. Urotensin II: Evidence for cardiac, hepatic and renal production. Peptides. 2005;26:2211–2214
   PubMed Web of Science ®Google Scholar
• Shenouda A, Douglas SA, Ohlstein EH, et al. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem. 2002;50:885–889
   PubMed Web of Science ®Google Scholar
• Mori N, Hirose T, Nakayama T, et al. Increased expression of urotensin II-related peptide and its receptor in kidney with hypertension or renal failure. Peptides. 2009;30:400–448
   PubMed Web of Science ®Google Scholar
• Magdalena B, Michał H, Fryderyk P, et al. Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome? Arch Med Sci. 2012;8:449–454
   PubMed Web of Science ®Google Scholar
• Zhang AY, Chen YF, Zhang DX, et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol. 2003;285:792–798
   PubMed Web of Science ®Google Scholar
• Ovcharenko E, Abbasi Z, Rubinstein I, et al. Renal effects of human urotensin-II in rats with experimental congestive heart failure. Nephrol Dial Transplant. 2006;21:1205–1211
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470
   PubMed Web of Science ®Google Scholar
• Wabel P, Chamney P, Moissl U, et al. Importance of whole-body bioimpedance spectroscopy for the management of fluid balance. Blood Purif. 2009;27:75–80
   PubMed Web of Science ®Google Scholar
• Moissl UM, Wabel P, Chamney PW, et al. Body fluid volume determination via body composition spectroscopy in health and disease. Physiol Meas. 2006;27:921–933
   PubMed Web of Science ®Google Scholar
• Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE Consensus Statement on Methodology and Indications Endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24:277–313
   PubMed Web of Science ®Google Scholar
• Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension. 1987;9:19–26
   Web of Science ®Google Scholar
• Teichholz LE, Kreulen T, Herman MV, et al. Problems in echocardiographic volume determinations: Echocardiographic–angiographic correlations in the presence of absence of asynergy. Am J Cardiol. 1976;37:7–11
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;12:1440–1463
   Google Scholar
• O’Rourke MF, Nichols WW. Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension. Hypertension. 2005;45:652–658
   PubMed Web of Science ®Google Scholar
• Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–585
   PubMed Web of Science ®Google Scholar
• Bongartz LG, Cramer MJ, Doevendans PA, et al. The severe cardiorenal syndrome: ‘Guyton revisited’. Eur Heart J. 2005;26:11–17
   PubMed Web of Science ®Google Scholar
• Tsai YC, Tsai JC, Chen SC, et al. Association of fluid overload with kidney disease progression in advanced CKD: Prospective cohort study. Am J Kidney Dis. 2014;63:68–75
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
   PubMed Web of Science ®Google Scholar
• Khan SQ, Bhandari SS, Quinn P, Davies JE, Ng LL. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol. 2007;117:323–328
   PubMed Web of Science ®Google Scholar
• Totsune K, Takahashi K, Arihara Z, et al. Role of urotensin II in patients on dialysis. Letter to the Editor. Lancet. 2001;358:810–811
   PubMed Web of Science ®Google Scholar
• Russell F, Molenaar P, O’Brien D. Cardiostimulant effects of urotensin II in human heart in vitro. Br J Pharmacol. 2001;132:5–9
   PubMed Web of Science ®Google Scholar